High-dose ziprasidone-induced acute dystonia

Department of Psychiatry, Columbia University, New York, New York, United States
Progress in Neuro-Psychopharmacology and Biological Psychiatry (Impact Factor: 3.69). 04/2007; 31(2):546-7. DOI: 10.1016/j.pnpbp.2006.10.005
Source: PubMed

ABSTRACT There are few clinical data describing the relative risks of extrapyramidal symptoms (EPS) at higher doses of ziprasidone (i.e., greater than 160 mg/day) when compared to lower doses. We report on a patient who displayed no EPS with ziprasidone 160 mg/day for several months, but did display marked, acute dystonic reactions on ziprasidone 240 mg/day. The observations from the present case indicate that high-dose, ziprasidone-induced acute dystonia may occur even if no such side effects have been experienced at doses up to and including 160 mg/day.

7 Reads
  • Source
    • "This analysis did not examine doses of ziprasidone greater than 160 mg/d. While there are no published randomized controlled studies of ziprasidone at doses that exceed 160 mg/d, several case reports and series describe the potential benefits and drawbacks of higher " off-label " dosing in schizophrenia and other disorders (Deutschman and Deutschman, 2007; Mech, 2008; Rosenfield et al., 2007; Levy et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to evaluate the relationship between maximum dose of ziprasidone and time to discontinuation in the treatment of schizophrenia/schizoaffective disorder and bipolar disorder in clinical practice. The 2001-2006 MarketScan Commercial and Medicare Databases were analyzed for maximum ziprasidone doses achieved in patients with schizophrenia/schizoaffective disorder or bipolar disorder. Ziprasidone maximum-dose groups were defined as low (20-60 mg/d), medium (61-119 mg/d), or high (120-160 mg/d). Patients receiving >160 mg/d were excluded. Mean time to discontinuation was evaluated across propensity score-matched dosing groups. Cox proportional hazard models were used to adjust for confounding when comparing the high- and medium-dose groups with the low-dose group. Data were available for 33,340 patients with schizophrenia/schizoaffective disorder, of whom 16.6% received low dose of ziprasidone, 22.0% medium dose, and 61.4% high dose. Of those subjects with bipolar disorder (n=27,751), 26.1% were receiving a low dose of ziprasidone, 25.7% a medium dose, and 48.3% a high dose. Among the propensity score-matched dosing groups, the respective mean time to discontinuation for low, medium, and high doses was 90.5, 117.2, and 201.6d within the schizophrenia/schizoaffective disorder cohort and 84.6, 110.7, and 173.2d within the bipolar cohort (p<0.0001 for all comparisons). The hazard ratios for discontinuing therapy were significantly lower for the medium- (0.84, 0.84) and high-dose (0.57, 0.60) groups relative to the low-dose group in schizophrenia/schizoaffective disorder and bipolar disorder, respectively. Patients with schizophrenia/schizoaffective or bipolar disorders receiving ziprasidone 120-160 mg/d experienced a statistically significant lower discontinuation rate compared with those receiving lower doses.
    Schizophrenia Research 10/2009; 115(2-3):115-20. DOI:10.1016/j.schres.2009.09.023 · 3.92 Impact Factor
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry 05/2007; 31(4):971-971. DOI:10.1016/j.pnpbp.2007.01.026 · 3.69 Impact Factor
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry 06/2007; 31(4):970; author reply 971. DOI:10.1016/j.pnpbp.2007.01.024 · 3.69 Impact Factor
Show more